OBJECTIVE: Adipose tissue (AT)-specific inflammation is considered to mediate the pathological consequences of obesity and macrophages are known to activate inflammatory pathways in obese AT. Because cyclooxygenases play a central role in regulating the inflammatory processes, we sought to determine the role of hematopoietic cyclooxygenase-1 (COX-1) in modulating AT inflammation in obesity. MATERIALS/ METHODS: Bone marrow transplantation was performed to delete COX-1 in hematopoietic cells. Briefly, female wild type (wt) mice were lethally irradiated and injected with bone marrow (BM) cells collected from wild type (COX-1+/+) or COX-1 knock-out (COX-1-/-) donor mice. The mice were fed a high fat diet for 16 weeks. RESULTS: The mice that received COX-1-/- bone marrow (BM-COX-1-/-) exhibited a significant increase in fasting glucose, total cholesterol and triglycerides in the circulation compared to control (BM-COX-1+/+) mice. Markers of AT-inflammation were increased and were associated with increased leptin and decreased adiponectin in plasma. Hepatic inflammation was reduced with a concomitant reduction in TXB2 levels. The hepatic mRNA expression of genes involved in lipogenesis and lipid transport was increased while expression of genes involved in regulating hepatic glucose output was reduced in BM-COX-1-/- mice. Finally, renal inflammation and markers of renal glucose release were increased in BM-COX-1-/- mice. CONCLUSION: Hematopoietic COX-1 deletion results in impairments in metabolic homeostasis which may be partly due to increased AT inflammation and dysregulated adipokine profile. An increase in renal glucose release and hepatic lipogenesis/lipid transport may also play a role, at least in part, in mediating hyperglycemia and dyslipidemia, respectively. Published by Elsevier Inc.
OBJECTIVE:Adipose tissue (AT)-specific inflammation is considered to mediate the pathological consequences of obesity and macrophages are known to activate inflammatory pathways in obese AT. Because cyclooxygenases play a central role in regulating the inflammatory processes, we sought to determine the role of hematopoietic cyclooxygenase-1 (COX-1) in modulating AT inflammation in obesity. MATERIALS/ METHODS: Bone marrow transplantation was performed to delete COX-1 in hematopoietic cells. Briefly, female wild type (wt) mice were lethally irradiated and injected with bone marrow (BM) cells collected from wild type (COX-1+/+) or COX-1 knock-out (COX-1-/-) donormice. The mice were fed a high fat diet for 16 weeks. RESULTS: The mice that received COX-1-/- bone marrow (BM-COX-1-/-) exhibited a significant increase in fasting glucose, total cholesterol and triglycerides in the circulation compared to control (BM-COX-1+/+) mice. Markers of AT-inflammation were increased and were associated with increased leptin and decreased adiponectin in plasma. Hepatic inflammation was reduced with a concomitant reduction in TXB2 levels. The hepatic mRNA expression of genes involved in lipogenesis and lipid transport was increased while expression of genes involved in regulating hepatic glucose output was reduced in BM-COX-1-/- mice. Finally, renal inflammation and markers of renal glucose release were increased in BM-COX-1-/- mice. CONCLUSION: Hematopoietic COX-1 deletion results in impairments in metabolic homeostasis which may be partly due to increased AT inflammation and dysregulated adipokine profile. An increase in renal glucose release and hepatic lipogenesis/lipid transport may also play a role, at least in part, in mediating hyperglycemia and dyslipidemia, respectively. Published by Elsevier Inc.
Authors: Alexandra Wibberley; Gerald P McCafferty; Christopher Evans; Richard M Edwards; J Paul Hieble Journal: Br J Pharmacol Date: 2006-05 Impact factor: 8.739
Authors: Bart M De Taeye; Tatiana Novitskaya; Owen P McGuinness; Linda Gleaves; Mousumi Medda; Joseph W Covington; Douglas E Vaughan Journal: Am J Physiol Endocrinol Metab Date: 2007-06-19 Impact factor: 4.310
Authors: Ganesan Murali; Ginger L Milne; Corey D Webb; Ann B Stewart; Ryan P McMillan; Brandon C Lyle; Matthew W Hulver; Viswanathan Saraswathi Journal: J Lipid Res Date: 2012-07-29 Impact factor: 5.922
Authors: R Langenbach; S G Morham; H F Tiano; C D Loftin; B I Ghanayem; P C Chulada; J F Mahler; C A Lee; E H Goulding; K D Kluckman; H S Kim; O Smithies Journal: Cell Date: 1995-11-03 Impact factor: 41.582
Authors: Jeb S Orr; Michael J Puglisi; Kate L J Ellacott; Carey N Lumeng; David H Wasserman; Alyssa H Hasty Journal: Diabetes Date: 2012-06-29 Impact factor: 9.461
Authors: Xia Lei; Qing Li; Susana Rodriguez; Stefanie Y Tan; Marcus M Seldin; John C McLenithan; Weiping Jia; G William Wong Journal: Am J Physiol Endocrinol Metab Date: 2015-03-03 Impact factor: 4.310
Authors: Andrew A Rebel; Siri A Urquhart; Kendra L Puig; Atreyi Ghatak; Stephen A Brose; Mikhail Y Golovko; Colin K Combs Journal: J Neurosci Res Date: 2015-02-22 Impact factor: 4.164
Authors: Julio Plaza-Díaz; Cándido Robles-Sánchez; Francisco Abadía-Molina; Virginia Morón-Calvente; María José Sáez-Lara; Alfonso Ruiz-Bravo; María Jiménez-Valera; Ángel Gil; Carolina Gómez-Llorente; Luis Fontana Journal: Sci Rep Date: 2017-05-16 Impact factor: 4.379